U.S. prices for the world's 20 top-selling medicines are, on average, three times higher than in Britain, according to an analysis carried out for Reuters.
The finding underscores a transatlantic gulf between the price of treatments for a range of diseases and follows demands for lower drug costs in America from industry critics such as Democratic presidential candidate Hillary Clinton.
The 20 medicines, which together accounted for 15 percent of global pharmaceuticals spending in 2014, are a major source of profits for companies including AbbVie (ABBV.N), AstraZeneca (AZN.L), Merck (MRK.N), Pfizer (PFE.N) and Roche (ROG.VX).
(Score: 3, Insightful) by pinchy on Thursday October 15 2015, @10:26PM
People who are in the healthcare business are going to fight it tooth and nail. All these expensive hospital bills lines someones pocket. Everyone from nurses/doctors/staff on up to pharmacy. They dont want the gravy train spoiled.